OBJECTIVES: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) are a new class of antidiabetic drugs that might increase the risk of dehydration and hypoglycemia, particularly during the month of Ramadan in which Muslims abstain from eating and drinking for 14-16 hours daily. We aimed to provide real-life evidence about the safety of SGLT2-I during Ramadan. METHODS: All patients over the age of 18 years on SGLT2-I before Ramadan 2016 who would be fasting during Ramadan were included. Demographic data, detailed medical history including comorbidities and medication profile, and laboratory results were collected before and after Ramadan. We also conducted a phone interview to evaluate the frequency and severity of hypoglycemia and dehydration. RESULTS: Of the total of 417 patients, 113 (27.0%) experienced hypoglycemic events, and 93 of these (82.3%) checked their blood glucose using a glucometer. Confirmed hypoglycemia (< 70 mg/dL) was observed in 78 (83.8%). The hypoglycemic events were significantly more frequent in the SGLT2-I plus insulin-treated group than in those treated with SGLT2-I plus oral hypoglycemic agents group (p < 0.001). Confirmed hypoglycemic events were more frequent in those using SGLT2-I plus intensive insulin compared to those using SGLT2-I plus basal insulin (p = 0.020). Symptoms of dehydration were seen in 9.3% (n = 39) of the total population. We observed statistically significant reductions in glycated hemoglobin and weight by the end of Ramadan (p < 0.001). There were no significant changes in lipid profile and creatinine levels by the end of the study. CONCLUSIONS: The use of insulin in combination with SGLT2-I increases the risk of hypoglycemia during Ramadan. Hypoglycemic events were mild and did not require hospital admission. However, careful monitoring during prolonged fasting is warranted. No significant harmful effects on renal function result from treatment with SGLT2-I during Ramadan.
OBJECTIVES: Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) are a new class of antidiabetic drugs that might increase the risk of dehydration and hypoglycemia, particularly during the month of Ramadan in which Muslims abstain from eating and drinking for 14-16 hours daily. We aimed to provide real-life evidence about the safety of SGLT2-I during Ramadan. METHODS: All patients over the age of 18 years on SGLT2-I before Ramadan 2016 who would be fasting during Ramadan were included. Demographic data, detailed medical history including comorbidities and medication profile, and laboratory results were collected before and after Ramadan. We also conducted a phone interview to evaluate the frequency and severity of hypoglycemia and dehydration. RESULTS: Of the total of 417 patients, 113 (27.0%) experienced hypoglycemic events, and 93 of these (82.3%) checked their blood glucose using a glucometer. Confirmed hypoglycemia (< 70 mg/dL) was observed in 78 (83.8%). The hypoglycemic events were significantly more frequent in the SGLT2-I plus insulin-treated group than in those treated with SGLT2-I plus oral hypoglycemic agents group (p < 0.001). Confirmed hypoglycemic events were more frequent in those using SGLT2-I plus intensive insulin compared to those using SGLT2-I plus basal insulin (p = 0.020). Symptoms of dehydration were seen in 9.3% (n = 39) of the total population. We observed statistically significant reductions in glycated hemoglobin and weight by the end of Ramadan (p < 0.001). There were no significant changes in lipid profile and creatinine levels by the end of the study. CONCLUSIONS: The use of insulin in combination with SGLT2-I increases the risk of hypoglycemia during Ramadan. Hypoglycemic events were mild and did not require hospital admission. However, careful monitoring during prolonged fasting is warranted. No significant harmful effects on renal function result from treatment with SGLT2-I during Ramadan.
Entities:
Keywords:
Diabetes Mellitus, Type 2; Fasting; SGLT2; Safety
Authors: S R Aravind; Khaled Al Tayeb; Shaiful Bahari Ismail; Naim Shehadeh; Ghaida Kaddaha; Rose Liu; Robert Balshaw; Nadia Lesnikova; Olaf Heisel; Cynthia J Girman; Bret J Musser; Michael J Davies; Harvey L Katzeff; Samuel S Engel; Larry Radican Journal: Curr Med Res Opin Date: 2011-04-20 Impact factor: 2.580
Authors: Ibrahim Salti; Eric Bénard; Bruno Detournay; Monique Bianchi-Biscay; Corinne Le Brigand; Céline Voinet; Abdul Jabbar Journal: Diabetes Care Date: 2004-10 Impact factor: 19.112
Authors: Mahmoud Ibrahim; Megahed Abu Al Magd; Firas A Annabi; Samir Assaad-Khalil; Ebtesam M Ba-Essa; Ibtihal Fahdil; Sehnaz Karadeniz; Terry Meriden; Aly A Misha'l; Paolo Pozzilli; Samad Shera; Abraham Thomas; Suhad Bahijri; Jaakko Tuomilehto; Temel Yilmaz; Guillermo E Umpierrez Journal: BMJ Open Diabetes Res Care Date: 2015-06-16
Authors: Md Faruque Pathan; Rakesh Kumar Sahay; Abdul Hamid Zargar; Syed Abbas Raza; A K Azad Khan; Mohammed Ashraf Ganie; Nazrul Islam Siddiqui; Firoz Amin; Osama Ishtiaq; Sanjay Kalra Journal: Indian J Endocrinol Metab Date: 2012-07
Authors: Mir Iftikhar Bashir; Md Faruque Pathan; Syed Abbas Raza; Jamal Ahmad; A K Azad Khan; Osama Ishtiaq; Rakesh K Sahay; Aisha Sheikh; Abdul Hamid Zargar Journal: Indian J Endocrinol Metab Date: 2012-07
Authors: Mahmoud Ibrahim; Melanie J Davies; Ehtasham Ahmad; Firas A Annabi; Robert H Eckel; Ebtesam M Ba-Essa; Nuha Ali El Sayed; Amy Hess Fischl; Pamela Houeiss; Hinde Iraqi; Ines Khochtali; Kamlesh Khunti; Shabeen Naz Masood; Safia Mimouni-Zerguini; Samad Shera; Jaakko Tuomilehto; Guillermo E Umpierrez Journal: BMJ Open Diabetes Res Care Date: 2020-05
Authors: Dana Abdelrahim; MoezAlIslam E Faris; Mohamed Hassanein; Ayman Z Shakir; Ayesha M Yusuf; Aljohara S Almeneessier; Ahmed S BaHammam Journal: Front Endocrinol (Lausanne) Date: 2021-03-08 Impact factor: 5.555